DOUBLE - HIT NON- HODGKIN'S LARGE B-CELLS LYMPHOMAS IS MORE FREQUENT THAN WE THINK, BUT IPI SCORE IS NOT THE PREDICTOR GOOD ENOUGH TO RECOGNIZE THIS TYPE OF LYMPHOMA
(Abstract release date: 05/19/16)
EHA Library. Sretenovic S. 06/09/16; 134609; PB1709
Dr. Snezana Sretenovic
Contributions
Contributions
Abstract
Abstract: PB1709
Type: Publication Only
Background
Diffuse large B-cell lymphoma (DLBCL) exhibits various morphologies, immunophenotypes, genetic aberrations, and clinical courses. These features vary across geographic regions, suggesting geographic heterogeneity as a characteristic of this type of lymphoma. DLBCL constitutes 31–34% of all non-Hodgkin's lymphomas in western countries, but in poor countries up to 50%. DLBCL is classified as the lymphoma with different entity in the recently published classification of the World Health Organization (WHO classification). Double-hit lymphomas (DHLs), as currently defined by the World Health Organization classification, are those lymphomas expressing the co-occurrence of MYC and BCL2 or BCL6 rearrangement as detected by fluorescence in situ hybridization (FISH) or standard cytogenetics.
Aims
Is the IPI score good predictor for recognize Double Hit in DLBC lymphomas.
Methods
We studied 62 patients with de novo DLBCL over the last six years and investigated the prognostic relevance of BCL-2 and C-MYC rearrangements positivity found by FISH. The prognostic significance of BCL-2 and C-MYC expression was evaluated within the context of DLBCL different subtypes and IPI score, but all treated with R-CHOP/ 21 day. Statistical analysis was performed by SPSS for Windows (22.0) and significance of p<0,05.
Results
We studied 62 patients with DLBCL, male 32 and female 30, mean age was 59,76+14,38 year. 58% of patients had high and intermediate high IPI score , whilst 42% of patients had low IPI score. With CS IV and III was 82% and only 18% had CS I and II. Patients with BCL-2 and C- MYC positivity found by FISH (13/62) – double hit, had a bad outcome and median OS was only 14 months. ECOG performance status 0 and 1 had 71% patients. No statistically significant differences in the frequency of BCL-2+ between the group with low vs high IPI risk, ( χ2-test, p = 0,492). There was no statistically significant difference in the incidence of C-MYC+ between the group of high and low IPI risk, (χ2-test, p = 0,426). Intergroup analysis of the group of high vs low risk IPI, both positive, both negative or at least one negative gene polymorphism did not show statistically significant difference,( χ2-test, p = 0,884).
Conclusion
Although currently available techniques such as immunohistochemistry may still be used, whole genomic analytic techniques like FISH will likely play a major role in the evaluation of patients in the future to determine optimal personalized treatment, but FISH is exspensive and IPI score is not good enough to recognize double-hit.
Session topic: E-poster
Keyword(s): BCL2, C-myc, Diffuse large B cell lymphoma
Type: Publication Only
Background
Diffuse large B-cell lymphoma (DLBCL) exhibits various morphologies, immunophenotypes, genetic aberrations, and clinical courses. These features vary across geographic regions, suggesting geographic heterogeneity as a characteristic of this type of lymphoma. DLBCL constitutes 31–34% of all non-Hodgkin's lymphomas in western countries, but in poor countries up to 50%. DLBCL is classified as the lymphoma with different entity in the recently published classification of the World Health Organization (WHO classification). Double-hit lymphomas (DHLs), as currently defined by the World Health Organization classification, are those lymphomas expressing the co-occurrence of MYC and BCL2 or BCL6 rearrangement as detected by fluorescence in situ hybridization (FISH) or standard cytogenetics.
Aims
Is the IPI score good predictor for recognize Double Hit in DLBC lymphomas.
Methods
We studied 62 patients with de novo DLBCL over the last six years and investigated the prognostic relevance of BCL-2 and C-MYC rearrangements positivity found by FISH. The prognostic significance of BCL-2 and C-MYC expression was evaluated within the context of DLBCL different subtypes and IPI score, but all treated with R-CHOP/ 21 day. Statistical analysis was performed by SPSS for Windows (22.0) and significance of p<0,05.
Results
We studied 62 patients with DLBCL, male 32 and female 30, mean age was 59,76+14,38 year. 58% of patients had high and intermediate high IPI score , whilst 42% of patients had low IPI score. With CS IV and III was 82% and only 18% had CS I and II. Patients with BCL-2 and C- MYC positivity found by FISH (13/62) – double hit, had a bad outcome and median OS was only 14 months. ECOG performance status 0 and 1 had 71% patients. No statistically significant differences in the frequency of BCL-2+ between the group with low vs high IPI risk, ( χ2-test, p = 0,492). There was no statistically significant difference in the incidence of C-MYC+ between the group of high and low IPI risk, (χ2-test, p = 0,426). Intergroup analysis of the group of high vs low risk IPI, both positive, both negative or at least one negative gene polymorphism did not show statistically significant difference,( χ2-test, p = 0,884).
Conclusion
Although currently available techniques such as immunohistochemistry may still be used, whole genomic analytic techniques like FISH will likely play a major role in the evaluation of patients in the future to determine optimal personalized treatment, but FISH is exspensive and IPI score is not good enough to recognize double-hit.
Session topic: E-poster
Keyword(s): BCL2, C-myc, Diffuse large B cell lymphoma
Abstract: PB1709
Type: Publication Only
Background
Diffuse large B-cell lymphoma (DLBCL) exhibits various morphologies, immunophenotypes, genetic aberrations, and clinical courses. These features vary across geographic regions, suggesting geographic heterogeneity as a characteristic of this type of lymphoma. DLBCL constitutes 31–34% of all non-Hodgkin's lymphomas in western countries, but in poor countries up to 50%. DLBCL is classified as the lymphoma with different entity in the recently published classification of the World Health Organization (WHO classification). Double-hit lymphomas (DHLs), as currently defined by the World Health Organization classification, are those lymphomas expressing the co-occurrence of MYC and BCL2 or BCL6 rearrangement as detected by fluorescence in situ hybridization (FISH) or standard cytogenetics.
Aims
Is the IPI score good predictor for recognize Double Hit in DLBC lymphomas.
Methods
We studied 62 patients with de novo DLBCL over the last six years and investigated the prognostic relevance of BCL-2 and C-MYC rearrangements positivity found by FISH. The prognostic significance of BCL-2 and C-MYC expression was evaluated within the context of DLBCL different subtypes and IPI score, but all treated with R-CHOP/ 21 day. Statistical analysis was performed by SPSS for Windows (22.0) and significance of p<0,05.
Results
We studied 62 patients with DLBCL, male 32 and female 30, mean age was 59,76+14,38 year. 58% of patients had high and intermediate high IPI score , whilst 42% of patients had low IPI score. With CS IV and III was 82% and only 18% had CS I and II. Patients with BCL-2 and C- MYC positivity found by FISH (13/62) – double hit, had a bad outcome and median OS was only 14 months. ECOG performance status 0 and 1 had 71% patients. No statistically significant differences in the frequency of BCL-2+ between the group with low vs high IPI risk, ( χ2-test, p = 0,492). There was no statistically significant difference in the incidence of C-MYC+ between the group of high and low IPI risk, (χ2-test, p = 0,426). Intergroup analysis of the group of high vs low risk IPI, both positive, both negative or at least one negative gene polymorphism did not show statistically significant difference,( χ2-test, p = 0,884).
Conclusion
Although currently available techniques such as immunohistochemistry may still be used, whole genomic analytic techniques like FISH will likely play a major role in the evaluation of patients in the future to determine optimal personalized treatment, but FISH is exspensive and IPI score is not good enough to recognize double-hit.
Session topic: E-poster
Keyword(s): BCL2, C-myc, Diffuse large B cell lymphoma
Type: Publication Only
Background
Diffuse large B-cell lymphoma (DLBCL) exhibits various morphologies, immunophenotypes, genetic aberrations, and clinical courses. These features vary across geographic regions, suggesting geographic heterogeneity as a characteristic of this type of lymphoma. DLBCL constitutes 31–34% of all non-Hodgkin's lymphomas in western countries, but in poor countries up to 50%. DLBCL is classified as the lymphoma with different entity in the recently published classification of the World Health Organization (WHO classification). Double-hit lymphomas (DHLs), as currently defined by the World Health Organization classification, are those lymphomas expressing the co-occurrence of MYC and BCL2 or BCL6 rearrangement as detected by fluorescence in situ hybridization (FISH) or standard cytogenetics.
Aims
Is the IPI score good predictor for recognize Double Hit in DLBC lymphomas.
Methods
We studied 62 patients with de novo DLBCL over the last six years and investigated the prognostic relevance of BCL-2 and C-MYC rearrangements positivity found by FISH. The prognostic significance of BCL-2 and C-MYC expression was evaluated within the context of DLBCL different subtypes and IPI score, but all treated with R-CHOP/ 21 day. Statistical analysis was performed by SPSS for Windows (22.0) and significance of p<0,05.
Results
We studied 62 patients with DLBCL, male 32 and female 30, mean age was 59,76+14,38 year. 58% of patients had high and intermediate high IPI score , whilst 42% of patients had low IPI score. With CS IV and III was 82% and only 18% had CS I and II. Patients with BCL-2 and C- MYC positivity found by FISH (13/62) – double hit, had a bad outcome and median OS was only 14 months. ECOG performance status 0 and 1 had 71% patients. No statistically significant differences in the frequency of BCL-2+ between the group with low vs high IPI risk, ( χ2-test, p = 0,492). There was no statistically significant difference in the incidence of C-MYC+ between the group of high and low IPI risk, (χ2-test, p = 0,426). Intergroup analysis of the group of high vs low risk IPI, both positive, both negative or at least one negative gene polymorphism did not show statistically significant difference,( χ2-test, p = 0,884).
Conclusion
Although currently available techniques such as immunohistochemistry may still be used, whole genomic analytic techniques like FISH will likely play a major role in the evaluation of patients in the future to determine optimal personalized treatment, but FISH is exspensive and IPI score is not good enough to recognize double-hit.
Session topic: E-poster
Keyword(s): BCL2, C-myc, Diffuse large B cell lymphoma
{{ help_message }}
{{filter}}